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Abstract: Paliperidone extended-release tablet (paliperidone ER; INVEGATM) is an oral 
antipsychotic for the treatment of schizophrenia. The recommended dose range is 3–12 mg 
per day. Paliperidone ER utilizes the OROS® delivery system, which allows for once-daily 
dosing. Its pharmacokinetic proﬁ  le results in a more stable serum concentration. Paliperidone 
is 9-hydroxyrisperidone, the chief active metabolite of risperidone. It undergoes limited hepatic 
metabolism, thereby minimizing the risks of hepatic drug–drug and drug–disease interactions. 
Three 6-week trials in patients with acute schizophrenia reported that paliperidone ER was 
effective, well tolerated, and produced clinically meaningful improvements in personal and 
social functioning compared with placebo. Post-hoc analysis of these trials in various popula-
tions, including recently diagnosed, elderly and more severely ill patients, those with sleep 
disturbances and those with predominant negative symptoms demonstrated improvement as 
well. Paliperidone ER was also signiﬁ  cantly better than placebo in the prevention of symptom 
recurrence in a 6-month maintenance study. The most common clinically relevant adverse events 
associated with paliperidone ER were extrapyramidal symptoms, tachycardia and somnolence. 
The incidence of Parkinsonism, akathisia and use of anticholinergic medications increased in 
a dose-related manner. Further, modest QTc interval prolongation was observed but did not 
produce clinical symptoms. Similar to risperidone, paliperidone ER is associated with increases 
in serum prolactin levels. Overall, paliperidone ER was effective, well tolerated and provides 
a new treatment option for patients with schizophrenia.
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Introduction
Schizophrenia is a chronic disorder that affects about 1% of the world’s population. 
While presently available antipsychotics can ameliorate an acute exacerbation of posi-
tive symptoms (eg, hallucinations and delusions), their beneﬁ  t for deﬁ  cit, cognitive 
and mood symptoms are not as pronounced. Furthermore, the safety and tolerability 
of each agent may differ substantially, often determining the clinician’s initial choice 
of drug and patients’ willingness to adhere to treatment (Janicak et al 2006). Pali-
peridone extended-release tablet (paliperidone ER) (INVEGATM, Johnson & Johnson 
Pharmaceuticals, Titusville, NJ, USA), the 9-OH metabolite of risperidone, has recently 
received approval by the United States (US) Food and Drug Administration (FDA) 
and by the European Medicines Evaluation Agency (EMEA). This agent combines the 
efﬁ  cacy of risperidone with an innovative, osmotically-controlled oral delivery system 
called OROSTM, which releases the drug at a controlled rate speciﬁ  c to the properties 
of 9-OH risperidone (Conley et al 2006). This allows for once-daily dosing and can 
minimize the 24-hour peak-to-trough variation at steady state concentration (CSS). 
Furthermore, its limited hepatic metabolism may reduce drug–drug or drug–disease 
interactions and its novel delivery system allows for a drug-speciﬁ  c controlled release 
that produces a more sustained, even exposure over time. While 9-OH risperidone 
has been identiﬁ  ed as an important component of risperidone’s effects, it has not been 
studied previously as an antipsychotic for schizophrenia.Neuropsychiatric Disease and Treatment 2007:3(6) 870
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The purpose of this article is to review the pharmacodynamic, 
pharmacokinetic, efﬁ  cacy and safety/tolerability proﬁ  le of pali-
peridone ER, the major active metabolite of risperidone.
Methods
The background data to provide this review were derived 
from a search of PUBMED, EMBASE, and several inter-
national congresses (between January 2004 and May 2007) 
using the key word “paliperidone”. It should be noted that 
many of the studies discussed are presently available only 
in abstract form and have not been peer reviewed. The three 
acute pivotal studies and recurrence study, however, have all 
been accepted or published in peer-reviewed journals.
Results
OROS formulation
Paliperidone ER is formulated within an osmotically con-
trolled release oral delivery system called OROS. The OROS 
formulation delivers paliperidone at a controlled rate over 
a 24-hour period. The system consists of an osmotically 
active trilayer core surrounded by a semi-permeable mem-
brane. The trilayer core contains two drug layers and a push 
compartment (Figure 1). After administration, water passes 
through the semi-permeable membrane, thereby controlling 
the rate of passage into the tablet membrane core, which in 
turn, controls drug delivery (Conley et al 2006). The OROS 
technology results in reduced ﬂ  uctuations between drug peak 
and trough serum concentrations (eg, 38% paliperidone ER 
versus 125% risperidone immediate-release [IR]) (Rossenu 
et al 2007). To preserve the integrity of the OROS deliv-
ery system, the tablet should be swallowed whole and not 
chewed, split or crushed (INVEGA package insert 2007). 
Since the shell of the tablet is non-absorbable, prescribers 
should inform patients that the undissolved residue may be 
observed in their stool.
Pharmacodynamics/pharmacokinetics
of paliperidone ER
Pharmacodynamics
Paliperidone is a benzisoxazole derivative that demonstrates 
high afﬁ  nity for central dopamine2 and serotonin2A recep-
tors. In addition, it has afﬁ  nity for both alpha-adrenergic1 and 
2 and histaminic1 receptors. Paliperidone does not possess 
affinity for muscarinic-cholinergic and beta-adrenergic 
Figure 1 OROS delivery system. The osmotic push–pull tablet: cross-section of bilayer tablet before and after ingestion. Reprinted with permission from Conley R, Gupta SK, 
Sathyan G. 2006. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS®), an advanced oral delivery form. Curr Med Res Opin, 22:1879–92. Copyright 
© 2006 Informa Healthcare.
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receptors. In vitro, the enantiomers (+ and –) of paliperidone 
demonstrate similar pharmacologic activity.
Pharmacokinetics
The absolute oral bioavailability of paliperidone ER is 28% 
(INVEGA package insert 2007). Administration of this 
agent after a high-fat or high-calorie meal increased the 
maximum serum concentration and area under the curve 
values by 60% and 54%, respectively. While paliperidone 
ER can be taken without regard to meals, the presence of 
food may increase its exposure (INVEGA package insert 
2007). Patients in the clinical efﬁ  cacy trials, however, were 
dosed without regard to meal timing. The terminal half-
life of paliperidone ER is about 23 hours with steady state 
concentration attained in 4–5 days (Rossenu et al 2006; 
INVEGA package insert 2007).
Paliperidone ER is widely and rapidly distributed after 
oral administration. It is 74% protein bound, primarily to 
albumin and α1-acid glycoprotein. Paliperidone ER under-
goes very limited hepatic metabolism, with approximately 
60% of the unchanged drug eliminated renally and 11% 
eliminated unchanged in the feces (Vermeir et al 2005). 
Paliperidone ER does not appear to possess enzyme-inducing 
or enzyme-inhibiting properties as shown by the lack of CYP 
450 inhibition in in vitro studies in human liver microsome 
studies (INVEGA package insert 2007). Thus, it is less prone 
to hepatic drug–drug or drug–disease interactions. While 
paliperidone ER undergoes both active and passive renal 
elimination, its co-administration with trimethoprim, a potent 
organic cation inhibitor, did not signiﬁ  cantly alter its clear-
ance rates (Thyssen et al 2006a). Overall, the paliperidone 
ER pharmacokinetic proﬁ  le demonstrates dose proportional-
ity within the recommended clinical range of 3–12 mg/day 
(Rossenu et al 2006).
Hepatic impairment
There may be a higher incidence of liver problems (eg, 
alcohol-related; hepatitis C) in patients with schizophrenia 
compared with the general population (Carney et al 2006). In 
this context, the pharmacokinetic parameters of paliperidone 
ER were also assessed in patients with moderate hepatic 
impairment compared with healthy controls (Thyssen et al 
2006b). There were minimal differences in the terminal 
elimination half-life between these two groups (26.5 hours 
for hepatically impaired patients versus 23.6 hours for healthy 
subjects). In addition, there was a small reduction in the total 
exposure to paliperidone ER in the hepatically impaired 
patients. After correcting for reduced α1-acid glycoprotein 
binding secondary to hepatic impairment, however, the total 
exposure to paliperidone ER was similar between groups. The 
unbound paliperidone ER levels were slightly lower in the 
hepatically impaired group as compared with healthy controls. 
As the unbound drug is most relevant to safety and efﬁ  cacy, no 
dosage adjustment is recommended in these patients.
Renal impairment
The dose of paliperidone ER should be lowered in patients 
with moderate-to-severe renal impairment, since the elimi-
nation of paliperidone decreases with decreasing estimated 
creatinine clearance (INVEGA package insert 2007; Thyssen 
et al 2007). The exact dose of paliperidone ER should be 
individualized according to the patient’s renal function 
status. For patients with mild renal impairment (with a cre-
atinine clearance of  50 to  80 mL/min), the maximum 
recommended dose is 6 mg paliperidone ER once daily. For 
patients with moderate-to-severe renal impairment (with a 
creatinine clearance of 10 to  50 mL/min), the maximum 
recommended dose is 3 mg paliperidone ER once daily.
Efﬁ  cacy in acute trials
The acute efﬁ  cacy of paliperidone ER has been examined in 
three studies (Davidson et al 2007; Kane et al 2007; Marder 
et al 2007). These studies involved a 6-week (at least 14 days 
as an inpatient), double-blind, randomized, fixed-dose, 
placebo- and active-controlled (olanzapine 10 mg per day), 
parallel-group design. The primary outcome measure in all 
studies was the mean change in total Positive and Negative 
Syndrome Scale (PANSS) score. Secondary outcome mea-
sures included the Marder PANSS factor scores (Marder et al 
1997), response rates, Clinical Global Impressions–Severity 
(CGI-S) scores (Guy 1976) and Personal and Social Perfor-
mance (PSP) scale scores (Morosini et al 2000; Patrick et al 
2006). This last scale allows clinicians to rate personal and 
social functioning on a 100-point scale in 10-point increments 
(eg, 1–10 representing lack of autonomy in basic function-
ing; 91–100 representing excellent functioning). The scale 
considers four domains of behavior: socially useful activities, 
relationships, self-care, and disturbing and aggressive behav-
iors. Improvement by one category (ie, 10 points) reﬂ  ects a 
clinically meaningful change.
Marder et al conducted the ﬁ  rst study at 74 US centers 
(Marder et al 2007). It included patients with chronic schizo-
phrenia who were experiencing an acute exacerbation (ie, 
PANSS score range = 70–120; mean ± standard deviation [SD] 
baseline score = 94 ± 12) of their disorder. Four hundred and 
forty-four subjects were randomized and 192 (43%) completed Neuropsychiatric Disease and Treatment 2007:3(6) 872
Janicak and Winans
the study. The treatment arms included paliperidone ER (6 or 
12 mg ﬁ  xed doses), placebo, and olanzapine (10 mg). Since the 
olanzapine arm was an active control group to conﬁ  rm assay 
sensitivity, it was not included in the statistical models for efﬁ  -
cacy analyses. The demographic and baseline characteristics of 
the 432 intent-to-treat (ITT) patients (ie, randomized patients 
who received  1 dose of double-blind study drug and had  1 
post-baseline efﬁ  cacy measure) were similar across all groups 
(see Table 1). Rescue medications (primarily lorazepam) were 
used by approximately 75% of subjects in each group for a 
mean duration of approximately 8 days. The primary outcome 
measure was change in the PANSS total score from baseline 
to end point. Both doses of paliperidone ER separated to a 
statistically signiﬁ  cant degree in comparison with placebo 
(6 mg dose, p = 0.006; 12 mg dose, p   0.001). There was also 
a signiﬁ  cant difference from placebo at every post-baseline 
rating from Day 4 onward in the 6 mg dose group (p   0.05), 
and from Day 15 onward in the 12 mg dose group (p   0.05). 
Clinical response rates (deﬁ  ned by  30% improvement from 
the baseline PANSS total score) were also signiﬁ  cantly higher 
in the paliperidone groups versus the placebo group (6 mg = 
50% [p   0.03]; 12 mg = 51% [p = 0.012]; placebo = 34%). 
By comparison, the response rate in the olanzapine (10 mg) 
group was approximately 46%.
Substantially fewer subjects on paliperidone ER were 
classiﬁ  ed as “marked/severe/extremely severe” on the CGI-S 
scale at end point compared with baseline (6 mg = 57.6% 
to 26.1%; 12 mg = 64.0% to 20.7%; placebo = 60.0% to 
44.7%). By comparison, the olanzapine (10 mg) group went 
from 70.5% to 29.6%. While PSP scale scores improved 
in both paliperidone ER dose groups, only the 6 mg dose 
separated from placebo to a statistically signiﬁ  cant degree 
(p = 0.007).
The second trial by Kane et al was similar to the Marder 
study but had some important design differences. These 
included the involvement of sites in both the US and India 
and three ﬁ  xed doses of paliperidone ER (6, 9, and 12 mg). 
Six hundred and thirty patients entered and 415 (66%) 
completed the study (Kane et al 2007). Demographic and 
baseline characteristics, as well as use and duration of rescue 
medications (mainly lorazepam), were similar across the four 
treatment arms. All three doses of paliperidone ER separated 
to a statistically signiﬁ  cant degree from placebo based on the 
mean change in the PANSS total (p   0.001) and all ﬁ  ve 
Marder factor scores from baseline to end point (p   0.001). 
Mean PANSS total change scores with paliperidone ER 
were signiﬁ  cantly greater than placebo for the 12 mg dose 
from Day 4 onward (p   0.01), and for the 6 mg and 9 mg 
doses from Day 8 onward (p   0.05) (Figure 2). Response 
rates were almost double in the paliperidone ER groups 
(6 mg = 56%; 9 mg = 51%; 12 mg = 61%) versus placebo 
(30%; p   0.001). By comparison, the response rate in the 
olanzapine (10 mg) group was 52%.
Rates of discontinuation due to lack of efficacy 
were also lower in the paliperidone ER versus pla-
cebo group (6 mg = 16%; 9 mg = 16%; 12 mg = 10%; 
placebo = 40%). A substantially lower percentage of 
subjects were classified as “marked/severe/extremely 
severe” on the CGI-S score from baseline to end point 
(paliperidone: 6 mg = 63% to 21%; 9 mg = 57% to 23%;
12 mg = 64% to 16%) compared with placebo (60% to 51%). 
By comparison, the olanzapine (10 mg) group went from 
Table 1 Patient demographics and baseline characteristics in the intent-to-treat population
  Placebo  Paliperidone ER  Paliperidone ER  Olanzapine  Total
 (n = 105)  6 mg  12 mg  10 mg  (n = 432)
   (n = 111) (n = 111) (n = 105) 
Age (years)a  42.3 (10.7)  42.1 (10.2)  41.4 (10.7)  40.5 (11.0)  41.6 (10.7)
Sex (%)         
 Male  78  68  69  80  74
 Female  22  32  31  20  26
Race (%)         
 White  48  41  41  42  43
 Black  50  58  59  53  55
 Asian  0  0  0  4  1
 Other  2  1  1  1  1
Weight (kg)a  89.7 (20.3)  87.4 (19.4)  87.0 (21.6)  89.7 (23.2)  88.4 (21.1)
PANSS total scorea  93.6 (11.7)  92.3 (12.0)  94.1 (11.4)  94.9 (12.4)  93.7 (11.9)
aMean (standard deviation).
Abbreviations: ER, extended release; PANSS, Positive and Negative Syndrome Scale.
Adapted with permission from Marder SR, Kramer M, Ford L et al 2007. Efﬁ  cacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, 
placebo-controlled study. Biol Psychiatry, June 28; [Epub ahead of print] doi:10.1016/j.biopsych.2007.01.017. Copyright © 2007 Elsevier.Neuropsychiatric Disease and Treatment 2007:3(6) 873
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64% at baseline to 24% at end point. Finally, PSP scale 
scores improved signiﬁ  cantly from baseline to end point for 
all three doses of paliperidone ER compared with placebo 
(p   0.001) (Figure 3).
The third study by Davidson et al was also similar to the 
Marder and Kane studies with the following important differ-
ences. This was a multi-center, international trial that included 
three ﬁ  xed doses of paliperidone ER (3 mg, 9 mg, and 15 mg). 
Six hundred and eighteen patients were randomized and 365 
(59%) completed the study (Davidson et al 2007). As in the 
Marder et al and Kane et al trials, demographic and baseline 
characteristics, as well as the use and duration of rescue medi-
cations, were similar across all groups.
All paliperidone ER doses produced significantly 
greater improvements in the PANSS total and Marder fac-
tor scores at end point versus placebo (p   0.01). All three 
doses demonstrated statistically signiﬁ  cant improvement 
from placebo by Day 4 onward. More than twice as many 
patients in all three paliperidone ER groups achieved a 
clinical response at end point versus placebo (3 mg = 40%; 
9 mg = 46%; 15 mg = 53%; placebo = 18%; p   0.005). 
By comparison, the proportion of responders in the olan-
zapine (10 mg) active control group at end point was 52%. 
Rates of discontinuation due to lack of efﬁ  cacy were lower 
in the paliperidone ER groups compared with placebo 
and decreased in a dose-related manner (ie, 3 mg = 24%; 
9 mg = 18%; 15 mg = 12%; placebo = 44%). By compari-
son, the olanzapine (10 mg) active control group had a 13% 
discontinuation rate due to inefﬁ  cacy.
A signiﬁ  cant improvement in the mean PSP scale scores 
(± SD) from baseline to end point was also seen for all three 
doses of paliperidone ER versus placebo (3 mg = 8.3 ± 17.1; 
Figure 2 Change in positive and negative symptom scale total score over time in the intent-to-treat populationa (Kane et al. 2007). Improvement in mean PANSS total score 
for paliperidone ER versus placebo was statistically signiﬁ  cant at every post-baseline time point from Day 4 (ﬁ  rst observation point) for paliperidone ER 12 mg (p   0.01 
versus change in placebo group), and from Day 8 for the paliperidone ER 6 and 9 mg groups (p   0.05 versus change in placebo group). This was maintained for the remainder 
of the study in both groups. aLast-observation carried forward; bPaliperidone ER 6 mg, p   0.05; cPaliperidone ER 9 mg, p   0.05; dPaliperidone ER 12 mg, p   0.01.
Abbreviations: ER, extended-release; SE, standard error.
Reprinted with permission from Kane J, Canas F, Kramer M et al 2007. Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled 
trial. Schizophrenia Res, 90:147–61.Copyright © 2007 Elsevier.
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9 mg = 7.6 ± 14.2; 15 mg = 12.2 ± 15.7; placebo = –1.5 ± 15.8; 
p   0.001). By comparison, the olanzapine (10 mg) active 
control group improved 7.8 ± 15.0 points on the PSP scale.
Finally, substantially fewer patients in the paliperidone 
ER groups were classiﬁ  ed as “marked/severe/extremely 
severe” from baseline to end point on the CGI-S scale ver-
sus the placebo group (3 mg = 54% to 32%; 9 mg = 52% 
to 23%; 15 mg = 57% to 17%; placebo = 56% to 49%). By 
comparison, the olanzapine (10 mg) group went from 56% 
at baseline to 21% at end point.
An analysis of the pooled data from these three trials was 
conducted to clarify the main outcomes and detect any pos-
sible clinically meaningful trends (Meltzer et al 2006). The 
major ﬁ  nding indicated that, while all doses used in these 
trials (3, 6, 9, 12, and 15 mg) were efﬁ  cacious, the 3 mg dose 
was least effective. Thus, paliperidone ER 6 mg per day is the 
suggested starting dose for treatment of schizophrenia.
Efﬁ  cacy in speciﬁ  c populations
and symptoms
Elderly patients with schizophrenia
It is also important to assess the impact of antipsychotics in 
an older population given their high rates of polypharmacy, 
multiple co-morbid medical illnesses, age-related changes 
in metabolism, increased sensitivity to adverse events (AEs) 
and the potential for longer length of illness to compromise 
clinical efﬁ  cacy. In this context, Tzimos et al conducted a 
6-week, double-blind, randomized, ﬂ  exible-dose, placebo-
controlled trial in 114 patients with schizophrenia  65 years 
(Tzimos et al 2007). The mean age of the subject population 
was 69.7 ± 4.5 years. The primary goal of this study was 
to assess the safety and tolerability of ﬂ  exible doses (3–12 
mg/day) of paliperidone ER compared with placebo. Initially, 
subjects were randomized to paliperidone ER (6 mg/day) 
or placebo in a 2:1 ratio. After 1 week, the paliperidone ER 
dose was increased to 9 mg/day (tolerability permitting) 
and, subsequently, ﬂ  exibly adjusted between 3–12 mg/day 
in 3 mg dose increments or decrements. Relevant baseline 
clinical characteristics were similar between the two treat-
ment arms. Eighty-four percent of the paliperidone ER group 
and 68% of the placebo group completed the study. Rescue 
medications (ie, benzodiazepines) were used in 26% of sub-
jects in both groups. The mean modal dose of paliperidone 
ER was 8.3 ± 3.0 mg/day. Of note, treatment-emergent AEs 
(TEAEs) occurred in 67% of the active drug group and 
71% of the placebo group. Serious AEs (SAEs) occurred in 
3% of the active drug group and 8% of the placebo group. 
Two deaths (both in the placebo group) also occurred. In 
terms of cardiovascular, cerebrovascular, neuromotor and 
metabolic changes, only tachycardia was more prevalent in 
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Figure 3 Improvements in social and personal functioning, measured using the Personal and Social Performance scale in the intent-to-treat populationa (Kane et al 2007). 
Personal and Social Performance scale scores improved signiﬁ  cantly from baseline to end point for all the paliperidone ER groups versus placebo (p   0.001 for all doses). 
aLast-observation carried forward.
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the paliperidone ER group (16%) compared with the placebo 
group (0%). This, however, did not lead to any clinically 
relevant events. Furthermore, improvements in the PANSS 
total and Marder factor scores, the CGI-S score, and percent 
of responders at end point all favored paliperidone ER over 
placebo. The authors concluded that paliperidone ER was 
safe, well tolerated and effective in reducing symptoms of 
schizophrenia in this older age group.
Sleep symptoms
Disrupted sleep is common in patients with schizophrenia and 
can cause subsequent daytime fatigue, precipitate exacerba-
tions and prolong time to recovery. In this context, Luthringer 
et al (2007) conducted a randomized, double-blind, placebo-
controlled, 3-week study in patients (n = 42) with schizophre-
nia-related insomnia to assess the effect of paliperidone ER 
(dosed Q AM) on sleep architecture. They also assessed the 
effect of this antipsychotic on patient-rated changes in sleep 
quality and daytime drowsiness based on the pooled data 
from the three pivotal trials. Overall, the data suggested that 
paliperidone ER had a positive effect on sleep architecture, 
continuity and patient-rated sleep quality without producing 
or worsening daytime sleepiness (Luthringer et al 2007).
Patients recently diagnosed
with schizophrenia
There are two important considerations in managing patients 
who have been recently diagnosed with schizophrenia. The 
ﬁ  rst is that early pharmacologic intervention may favorably 
alter the long-term prognosis by controlling symptoms, pro-
longing remission and preventing future episodes (or at least 
decreasing their frequency and severity). The second is that 
while patients early in the course of their illness may be more 
responsive to medication treatment, they may also be more 
sensitive to AEs. In this context, Kostic et al conducted a post 
hoc analysis of the data from the three, 6-week acute trials 
focusing on those patients diagnosed with schizophrenia within 
5 years of study entry (Kostic et al 2006a, b). The data from 
patients diagnosed more than 5 years before study entry were 
also analyzed separately for reference to such key variables as 
baseline clinical characteristics and efﬁ  cacy/tolerability end 
points (eg, PANSS, AEs). Four hundred and thirteen patients 
met the recently diagnosed criterion of  5 years with the 
mean time ill being 2.8 ± 1.4 years for those on paliperidone 
ER (3–12 mg; n = 284) and 2.8 ± 1.3 years for those on pla-
cebo (n = 100). Eight hundred and ninety-three patients were 
diagnosed  5 years prior to study entry. No differences in 
baseline demographics (with the exception of age and length 
of diagnosed illness) were evident between the two duration of 
illness groups. Completion rates and reasons for discontinua-
tion also did not differ between the  5 and  5 year duration of 
illness groups. Furthermore, both paliperidone ER duration of 
illness groups had about a 20% greater completion rate than the 
placebo group. Efﬁ  cacy measures (PANSS total, Marder factor 
scores, CGI-S scores and PSP scale scores) were signiﬁ  cantly 
improved from baseline in the  5 year group compared with 
placebo. Changes in PANSS total score were similar to those 
observed in the  5 year group (Kostic et al 2006a). These 
analyses suggest a comparable response in patients regardless 
of illness length. In addition, tolerability to paliperidone ER 
was similar between the two duration of illness groups, with 
the possible exceptions of greater vulnerability for movement-
disorder-related effects (eg, akathisia and pseudoparkinson-
ism) and somnolence in those recently diagnosed. The authors 
note that potential limitations of these analyses include the post 
hoc method; assignment to the duration of illness group based 
on history; and the lack of comprehensive data on duration of 
undiagnosed and untreated psychosis.
Severely ill patients with schizophrenia
In a post hoc analysis of the pooled data from the three acute 
efﬁ  cacy trials, Canuso and colleagues considered the impact 
of paliperidone ER (ﬁ  xed doses of 3–12 mg per day) in those 
subjects who presented with “marked to severe” symptom 
levels (Canuso et al 2006b). The pre-deﬁ  ned criterion was 
a baseline PANSS total score  105. Two hundred and sev-
enteen patients qualiﬁ  ed for the analysis with mean baseline 
PANSS scores of 111.4 ± 5.7 and 110.9 ± 4.3 in the active 
drug and placebo groups, respectively. At end point, the 
paliperidone ER group exhibited a signiﬁ  cantly greater 
improvement (p   0.05) than the placebo group in the mean 
PANSS total score (–26.7 versus –5.7, respectively); CGI-S 
score (–1.2 versus –0.1, respectively); and all PANSS factor 
scores. The most frequent AEs in the paliperidone ER versus 
placebo group were headache (17% versus 9%, respectively), 
agitation (6% versus 13%, respectively) and insomnia (14% 
versus 14%, respectively). Change scores on the Simpson 
Angus Scale (SAS) did not differ between groups. The 
authors concluded that paliperidone ER was effective and 
well tolerated in a more severely ill group of patients.
Negative symptoms
Deﬁ  cit or negative symptoms can be a major impediment to 
recovery, ability to function and quality of life. These symp-
toms may be a primary manifestation of the illness or may 
occur as secondary manifestations in relation to other aspects Neuropsychiatric Disease and Treatment 2007:3(6) 876
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of the disorder or its treatment (eg, affective symptoms and 
extrapyramidal symptoms [EPS]).
The impact of any treatment intervention may directly or 
indirectly affect negative symptoms. In this context, Canuso 
et al conducted a post hoc exploratory analysis of the pooled 
data from the three acute efﬁ  cacy trials with paliperidone 
ER to assess its beneﬁ  t for negative symptoms (Canuso et al 
2006a). Two types of analyses were employed: regression 
analysis and path analysis. Regression analyses exploring the 
relationship between baseline/study characteristics and nega-
tive symptoms demonstrated that duration of drug exposure 
signiﬁ  cantly predicted improvement in the PANSS negative 
symptom factor score (p   0.001). Furthermore, improve-
ment in PSP scale scores was signiﬁ  cantly associated with 
improvement in the PANSS negative symptom factor score 
(p   0.001). Path analysis models demonstrated that up to 
33% of negative symptom improvement resulted from a 
direct effect of the drug, while the indirect effects were medi-
ated through improvement in positive symptoms (51%) and 
anxiety/depressive symptoms (18%). Conversely, a 2.1% 
inverse effect on negative symptoms was accounted for by 
movement disorders as measured using the SAS (Figure 4). 
These analyses indicated a possible direct effect of paliperi-
done ER on negative symptoms.
In another post hoc analysis of this same data set, Dirks 
et al assessed the impact of paliperidone ER on patients 
with predominant negative symptoms (Dirks et al 2006). 
This was pre-deﬁ  ned as a baseline PANSS negative factor 
score  40% of the possible maximum plus a positive factor 
score  40% of the possible maximum. Two hundred and 
ninety-nine patients met these criteria with an average of 49% 
of the maximum negative symptoms score and 33% of the 
maximum positive symptoms score. Those with and without 
predominant negative symptoms demonstrated comparable 
baseline demographic characteristics. Those with predomi-
nant negative symptoms demonstrated signiﬁ  cant improve-
ments following treatment with paliperidone ER compared 
with placebo on the primary and secondary outcome mea-
sures with no unexpected tolerability ﬁ  ndings.
Patients previously treated
with risperidone or olanzapine
Further, separate post hoc analyses of the pooled data from the 
three, 6-week acute trials assessed the efﬁ  cacy of paliperidone 
ER compared with placebo in patients with acute schizophrenia 
who had been previously treated with risperidone (n = 198) 
or olanzapine (n = 153) immediately prior to study entry. The 
mean duration of risperidone treatment was 418.8 ± 573 days 
(paliperidone ER group) and 527.0 ± 805.3 (placebo group), 
with mean doses of 4.4 ± 2.5 mg/day and 4.1 ± 2.6 mg/day in 
the paliperidone ER and placebo groups, respectively. In the 
second analysis, the mean duration of olanzapine treatment 
was 490.1 ± 677.7 days for patients receiving paliperidone 
ER and 556.3 ± 817.3 days for those receiving placebo. Mean 
doses of olanzapine were 16.4 ± 8.1 mg/day and 17.0 ± 6.2 
mg/day for patients receiving paliperidone ER and placebo, 
respectively. In both analyses, these patients experienced 
a signiﬁ  cant improvement in mean PANSS total and factor 
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scores, PSP scale scores and CGI-S scores (Canuso et al 2007; 
Dirks et al 2007). The additional improvements in symptoms 
and functioning observed following a switch to paliperidone 
ER may be attributed to the continued use of antipsychotic 
medication over time.
Recurrence prevention
Once an acute exacerbation has been controlled, the focus of 
treatment becomes prevention of recurrence, preservation of 
functioning and minimization of AEs associated with long-term 
medication exposure. To this end, Kramer et al conducted a 
randomized, double-blind, placebo-controlled, parallel-group, 
long-term study to assess the efﬁ  cacy of paliperidone ER 
(ﬂ  exibly dosed between 3–15 mg/day) compared with placebo 
(Kramer et al 2007a). The design involved 5 phases (Figure 5). 
The primary outcome measure was time to ﬁ  rst recurrence in 
the double-blind phase. Recurrence was deﬁ  ned according to 
a series of pre-deﬁ  ned criteria (Table 2). Secondary outcome 
measures were change from baseline to end point on the 
PANSS total and CGI-S scores. Safety measures included 
self-reported AEs, SAS scores, Abnormal Involuntary 
Movement Scale (AIMS) scores, Barnes Akathisia Rating 
Scale (BARS) scores, clinical laboratory evaluations, weight 
and electrocardiograms. The initial dose of paliperidone ER 
(9 mg) was selected based on pre-clinical data and was made 
prior to the analysis of any pivotal study data.
The modal daily dose of paliperidone ER received during 
the double-blind phase was 9 mg by 39 (38%) patients, 15 mg 
by 29 (28%) patients, 12 mg by 23 (22%) patients, 6 mg by 9 
(9%) patients, and 3 mg by 4 (4%) patients (Kramer et al 2006). 
Based on the pre-deﬁ  ned criteria (Table 2), recurrence occurred 
in 52% of ITT patients on placebo and 22% on paliperidone 
ER. Moreover, 25% of patients experienced a recurrence on 
placebo at 23 days versus 83 days for those on paliperidone 
ER. Discontinuations in the double-blind phase were higher, 
however, in the paliperidone ER group (n = 20; 19%) com-
pared with placebo (n = 8; 8%). Subject choice contributed to 
this difference (12 on paliperidone ER versus 0 on placebo) 
(Kramer et al 2007a).
The PANSS total scores during the run-in and stabiliza-
tion phases went from 93.4 ± 11.2 to 52.2 ± 11.0 for the 
ITT population (Kramer et al 2006). During the run-in and 
stabilization phases, AEs were rated as mild or moderate 
in severity (Kramer et al 2006). The most frequent AEs 
Screening
(n=628)
Flexible dosing 3–15 mg/day
Run-in phase (n=530)
Paliperidone ER
Paliperidone ER
Stabilzation phase (n=312)
Fixed dose established during run-in phase
Double-blind phase (n=207)b
Up to 5 days
8 weeks
6 weeks
Variable durationa Placebo (n=102) Paliperidone ER (n=105)
Flexible dosing 3–15 mg/day
Completion of double-blind phase
Figure 5 Study design to assess efﬁ  cacy of paliperidone ER compared with placebo in relation to recurrence (Kramer et al 2007a). aUp to 24 weeks after last subject 
randomized, or 86 recurrence events, with preplanned interim analysis at 43 events; bIntent-to-treat population (n = 205), 1 patient lost to follow up, another patient did not 
receive any double-blind medication; cPatients who were in the study at the time of its termination were considered to have completed the entire course of the study.Neuropsychiatric Disease and Treatment 2007:3(6) 878
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(occurring in  10% of patients) included tremor (16%), 
headache (14%), hyperkinesia (12%) and insomnia (10%). 
Thirty SAEs occurred and were usually related to the psychotic 
disorder. They included psychosis (19 patients; 4%), suicide 
attempt (4 patients; 1%), agitation (2 patients; 1%) and aggres-
sive reaction (4 patients;  1%) (Kramer et al 2006).
At the end of the double-blind phase, CGI-S scores of  “mild/
very mild/not ill” were observed in 73% of the paliperidone ER 
group and 46% of the placebo group (Kramer et al 2006).
The authors concluded that paliperidone ER (ﬂ  exibly 
dosed at 3–15 mg/day) was superior to placebo in prevent-
ing recurrence after stabilization. In general, it was also well 
tolerated with longer-term exposure.
Safety and tolerability of paliperidone ER
Meltzer et al summarized the safety and tolerability 
for the three acute efﬁ  cacy trials with paliperidone ER 
(Meltzer et al 2006). Overall, TEAEs were reported in 66%–
77% of patients in the paliperidone groups compared with 
66% of patients in the placebo group. The most commonly 
observed AEs occurring in  5% of patients in any group 
included headache, anxiety and insomnia (See Table 3). 
SAEs were comparable in the paliperidone ER (5%–6%) 
and placebo groups (6%).
Extrapyramidal symptoms
In the Meltzer pooled analysis (Meltzer et al 2006) the 
incidence of EPS was comparable between the paliperi-
done ER 3 mg and 6 mg groups (13% and 10%, respec-
tively) and placebo (11%). In the paliperidone ER (9 mg 
and 12 mg) groups, the incidence of EPS-related AEs 
was approximately doubled (25% and 26% of patients, 
respectively). Based on outcomes of the SAS, AIMS and 
BARS scales, the majority of paliperidone ER-treated 
patients did not experience any changes in movement 
disorders. It should be noted that the pivotal studies were 
ﬁ  xed-dose trials; patients randomized to 9 or 12 mg/day 
were not titrated upward from 6 mg/day.
Metabolic and endocrine effects
Paliperidone ER (3–15 mg) produced a mean bodyweight 
change of  2 kg over the 6-week study period. Moreover, 
there were no clinically meaningful changes in glucose, 
insulin and blood lipid levels (Meyer et al 2006).
Kramer et al presented pooled data (n = 1083) from three 
open-label, 52-week paliperidone extension studies dosed 
between 3–15 mg/day (starting dose = 9 mg). The mean 
duration of study participation was 232 days and the mean 
modal dose of paliperidone was 10.1 mg/day. The serum 
glucose mean change to end point was 0.20 ± 01.27 mmol/L. 
Four patients had glucose elevations above the normal value 
and one had a glucose level below the normal range. The 
mean end point change in insulin levels was 2.8 ± 36.99 
μ/mL. These glucose and insulin changes were similar to 
those observed during the double-blind studies. There were 
no increases observed in the mean change in triglycerides, 
total cholesterol, low-density cholesterol or high-density 
cholesterol observed. The mean end point changes in body 
weight and body mass index (BMI) were 1.1 ± 5.47 kg and 
0.4 ± 1.96 kg/m2, respectively. Those patients with a lower 
initial BMI ( 18.5 kg/m2 at baseline) were more likely to 
gain weight compared with those with a higher initial BMI 
( 25 kg/m2 at baseline). The overall incidence of glucose-
related AEs was  1%, while the percentage of patients 
experiencing a weight increase-related AE was 5%. No 
patients discontinued due to glucose-related AEs or weight 
gain (Kramer et al 2007b).
Paliperidone ER elevates prolactin levels in a fashion 
similar to risperidone. In this context, some studies have 
found a statistically signiﬁ  cant correlation between serum 
9-OH risperidone and prolactin level elevation (Melkersson 
2006; Knegtering 2005). Conversely, others have not dem-
onstrated a correlation between serum prolactin levels and 
plasma concentrations of risperidone, 9-OH risperidone, or 
the active moiety, following oral administration of risperi-
done (Zhou 2006). In the acute trials, potential prolactin-
related AEs were reported in 1%–2% of subjects receiving 
placebo or paliperidone ER (3–12 mg/day), and 4% in those 
receiving paliperidone ER (15 mg/day).
Table 2 Deﬁ  nitions of recurrence (Kramer et al 2007a) 
Hospitalization 
PANSS score  25% increase for two consecutive
  days if baseline score was  40
  10 point increase, if baseline score was  4
Deliberate self-injury
and/or violent behavior
Suicidal or homicidal
ideation 
CGI-S score  Score  4 for 2 consecutive days
  if baseline score was  3
 Score   5 for 2 consecutive days
  if baseline score was 4
PANSS items (P1, P2, P3,   5 on any item for 2 consecutive days
P6, P7, G8) score  if baseline score was  3
   6 on any item for 2 consecutive days
  if baseline score was 4
Abbreviations: CGI-S, Clinical Global Impression–Severity; PANSS, Positive and 
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In the Marder et al study, potential prolactin-related AEs 
were experienced by 4 patients (0.9%), including 3 men (2 
patients on placebo, 1 patient on paliperidone ER 12 mg), and 1 
woman (on paliperidone ER 12 mg), but did not result in study 
discontinuation. Potential prolactin-related AEs were impotence 
and abnormal sexual function with placebo; and nonpuerperal 
lactation and decreased libido with paliperidone ER 12 mg. 
Elevations from baseline prolactin levels were observed at Day 
15, and subsequently decreased but not to within normal range 
by the end point (Table 4) (Marder et al 2007).
In the Kane et al study, potential prolactin-related AEs 
(including galactorrhea, gynecomastia, amenorrhea, anorgas-
mia and abnormal sexual function) were reported by 1% of 
patients – 3 men (1 in each of the paliperidone ER groups) 
and 4 women (1 in each of the paliperidone ER groups and 1 
in the olanzapine group) – and resulted in 2 study discontinu-
ations. Mean plasma prolactin levels increased from 17.4 ± 
19.9 ng/mL at baseline to 45.3 ± 23.19 ng/mL at end point 
in the male patients on paliperidone ER, and from 38.03 ± 
57.0 ng/mL at baseline to 124.5 ± 65.5 ng/mL at end point 
in the female patients on paliperidone ER. In contrast, mean 
prolactin levels decreased from baseline to end point in male 
and female subjects on placebo or olanzapine.
In the Davidson et al study, prolactin-related AEs (non-
puerperal lactation) and potential prolactin-related AEs 
(anorgasmia, impotence and decreased libido) were reported 
in 3 men (2 in the paliperidone ER 15 mg group and 1 in 
the olanzapine group) and 3 women (2 in the paliperidone 
ER 15 mg group and 1 in the paliperidone ER 3 mg group). 
None of these events were considered severe or led to study 
discontinuation. Plasma prolactin levels increased from 16.5 
± 17.5 ng/mL at baseline to 42.9 ± 29.1 ng/mL at end point in 
the males on paliperidone ER and from 36.6 ± 68.8 ng/mL at 
baseline to 120.2 ± 89.6 ng/mL at end point in the females on 
paliperidone ER (Davidson et al 2007). Again, mean prolactin 
levels decreased from baseline to end point in male and female 
patients on placebo or olanzapine (Davidson et al 2007).
When considering the effects of paliperidone ER on 
serum prolactin levels and the occurrence of potentially 
prolactin-related AEs, it must be recognized that these were 
spontaneously reported during the clinical studies, rather 
than as part of a systematic assessment. This may suggest 
Table 3 Incidence of treatment-emergent adverse events occurring in  5% of patients in any treatment group in the safety analysis 
set (Meltzer et al 2006)
 Placebo  Paliperidone  Paliperidone  Paliperidone  Paliperidone  Paliperidone
  –  ER 3 mg  ER 6 mg  ER 9 mg  ER 12 mg  ER 15 mg
 (n  = 355) n (%)  (n = 127) n (%)  (n = 235) n (%)  (n = 246) n (%)  (n = 242) n (%)  (n = 113) n (%)
TEAEs in total  235 (66)  91 (72)  156 (66)  171 (70)  184 (76)  87 (77)
Nervous system disorders
Headache  42 (12)  14 (11)  29 (12)  34 (14)  35 (14)  20 (18)
Akathisia  14 (4)  5 (4)  7 (3)  20 (8)  23 (10)  11 (10)
Extrapyramidal  8 (2)  6 (5)  5 (2)  17 (7)  18 (7)  9 (8) 
disorder 
Somnolence  12 (3)  6 (5)  8 (3)  17 (7)  11 (5)  7 (6)
Dizziness  14 (4)  7 (6)  11 (5)  11 (4)  12 (5)  7 (6)
Sedation  13 (4)  1 (1)  12 (5)  8 (3)  15 (6)  2 (2)
Psychiatric disorders
Insomnia  51 (4)  14 (11)  29 (12)  35 (14)  26 (11)  14 (12)
Anxiety  29 (8)  12 (9)  16 (7)  14 (6)  11 (5)  9 (8)
Agitation  28 (8)  7 (6)  17 (7)  13 (5)  13 (5)  3 (3)
Psychotic disorders  16 (5)  5 (4)  6 (3)  7 (3)  4 (2)  4 (4)
Gastrointestinal disorders
Nausea  19 (5)  8 (6)  9 (4)  10 (4)  10 (4)  2 (2)
Vomiting  17 (5)  2 (2)  6 (3)  9 (4)  12 (5)  8 (7)
Constipation  20 (6)  7 (6)  8 (3)  7 (3)  7 (3)  4 (4)
Dyspepsia  14 (4)  3 (2)  6 (3)  5 (2)  12 (5)  6 (5)
Cardiac disorders
Tachycardia  10 (3)  3 (2)  17 (7)  18 (7)  18 (7)  2 (2)
Sinus tachycardia  15 (4)  11 (9)  9 (4)  10 (4)  17 (7)  8 (7)
Investigations
Electrocardiogram QT  9 (3)  4 (3)  9 (4)  7 (3)  12 (5)  4 (4)
corrected interval prolonged
Abbreviations: ER, extended release; TEAE, treatment-emergent adverse event.Neuropsychiatric Disease and Treatment 2007:3(6) 880
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that the frequency of prolactin-related AEs associated with 
paliperidone ER therapy is underestimated.
Cardiac effects
Paliperidone causes a modest increase in the corrected QT 
interval (QTc). During the three acute trials, 15 QT measure-
ments were taken, including one measurement at the time 
of expected peak paliperidone ER serum concentration. The 
incidence of QTc prolongation on paliperidone ER ranged 
from 3% to 5% compared with 3% on placebo. Furthermore, 
there were no subjects who experienced a QTc interval  500 
msec. More speciﬁ  cally, in the Marder et al study, 1 (1%) 
patient on placebo, 2 (2%) patients on the 6 mg dose and 1 
(1%) patient on the 12 mg dose had a prolonged maximum 
post-baseline QTcLD (QTc linear derived) assessment (ie, 
 450 ms for males and  470 ms for females). In the Kane 
et al study no patient on paliperidone ER had a prolonged 
maximum post-baseline QTcLD assessment. In the Davidson 
et al study no patients on paliperidone ER had a post-baseline 
QTcLD interval exceeding 500 ms.
Two additional studies were conducted to assess the car-
diac effects of paliperidone ER. The ﬁ  rst was a controlled study 
with moxiﬂ  oxacin (400 mg dose) as an active control and a 
supratherapeutic dose of paliperidone IR, which provides at 
least twice the maximum exposure of paliperidone ER 12 mg. 
The 4 mg and 8 mg doses of paliperidone IR were associated 
with a QTc increase of 6.8 msec and 12.3 msec, respectively 
(INVEGA package insert 2007). The second study was a 
randomized, double-blind, placebo-controlled study evaluat-
ing the QTc intervals of patients treated with paliperidone and 
quetiapine (Hough et al 2007). In this study, paliperidone ER 
(12 or 18 mg/day) and quetiapine (400 mg twice daily) resulted 
in minimal QTc prolongation. Mean changes in QTcLD 
were paliperidone ER 12 mg/day, 1.71 ms versus quetiapine 
800 mg/day, 6.06 ms; paliperidone ER 18 mg/day, 3.70 ms; 
and quetiapine 800 mg/day, 5.57 ms.
Paliperidone ER should be avoided in combination with 
other drugs that are known to prolong the QTc duration 
including Class 1A (eg, quinidine, procainamide) or Class 
III (eg, amiodarone, sotalol) anti-arrhythmic medications; 
antipsychotic medications (eg, chlorpromazine, thioridazine); 
antibiotics (eg, gatiﬂ  oxacin, moxiﬂ  oxacin); or any other class 
of medications known to prolong the QTc interval. Addi-
tionally, paliperidone ER should also be avoided in patients 
with congenital long QT syndrome or a history of cardiac 
arrhythmias (INVEGA package insert 2007).
Long-term safety of paliperidone ER
During the double-blind phase of the recurrence study, TEAEs 
occurred at a similar rate in both treatment arms (35% in the 
paliperidone ER group and 40% in the placebo group) (Kramer 
et al 2007a). Only three of these (psychosis, aggressive reac-
tion, and insomnia) occurred in  5% of subjects. Psychosis 
and aggressive reaction were more frequent in the placebo 
compared with the paliperidone ER group (23% versus 7% 
and 6% versus 1%, respectively). Extrapyramidal symptoms 
were reported in 3% of patients in the placebo group and 
7% of patients in the paliperidone ER group. There were no 
occurrences of glucose-related AEs. Also, weight gain was 
modestly higher in the paliperidone ER versus placebo group 
(ie, 1.8 ± 4.8 kg versus 0.2 ± 5.0 kg, respectively) (Kramer et al 
2006). Prolactin-related AEs occurred in 4% of patients in the 
paliperidone ER group and 0% of the placebo group. In terms of 
tachycardia, there were no differences between the two groups 
(7% in the paliperidone ER group and 2% in the placebo group). 
Four subjects (2%) discontinued due to AEs (1 on placebo; 3 on 
paliperidone ER) (Kramer et al 2006). Additionally, a favorable 
long-term safety proﬁ  le was demonstrated in a pre-speciﬁ  ed, 
pooled analysis of the three 52-week, open-label extension 
phases from the Kane et al, Davidson et al and Marder et al 
studies (Eerdekens et al 2007). No notable changes in EPS 
symptoms were observed in terms of SAS, AIMS or BARS 
median scores. Potential prolactin-related AEs were reported in 
 1% (except for amenorrhea [4%]) of subjects who received 
paliperidone ER during both the double-blind and open-label 
phases of the studies. Mean plasma prolactin levels were also 
Table 4 Changes in prolactin levels (baseline to endpoint) (Marder et al 2007)
Treatment group  Mean ± SD prolactin levels (ng/mL)   Mean ± SD prolactin levels (ng/mL)
 (males)      (females)   
 Baseline  Endpoint  Baseline  Endpoint
Placebo 12.0  ± 10.0 12.4  ± 11.8  20.3 ± 24.3 25.3  ± 31.8
Paliperidone ER (6 mg)  13.4 ± 11.4 36.2  ± 33.6 23.4  ± 21.4 104.8  ± 77.5
Paliperidone ER (12 mg)  15.6 ± 19.6 39.9  ± 26.9 35.4  ± 43.4 111.8  ± 74.9
Olanzapine 14.4  ± 18.8 18.4  ± 16.5 17.0  ± 10.9 22.9  ± 14.4
Abbreviations: Safety analysis set; SD, standard deviation.Neuropsychiatric Disease and Treatment 2007:3(6) 881
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observed to decrease over the course of the open-label phases. 
Only 1% of subjects had a prolonged maximum post-baseline 
QTcLD  450 ms, and one patient experienced a maximum 
post-baseline QTcLD  480 ms.
Future directions
Additional efﬁ  cacy studies in acute mania and for the long-
term treatment of schizophrenia are in progress. Furthermore, 
a placebo-controlled, head-to-head comparison of paliperidone 
ER and quetiapine for treatment of an acute exacerbation of 
schizophrenia is ongoing. In the absence of a risperidone/pali-
peridone head-to-head trial, a “virtual” analysis comparing 
6-week data from double-blind, placebo-controlled studies of 
risperidone and paliperidone ER in patients suffering an acute 
exacerbation of schizophrenia has been conducted (Schooler 
et al 2006). This post hoc analysis attempted to assess how 
paliperidone ER compares to risperidone with respect to 
efﬁ  cacy and tolerability. Patient populations were matched 
based on age (18–65 years); exposure to a conventional anti-
psychotic within 90 days of study entry; and treatment with 
paliperidone ER (3–12 mg/day), risperidone (2–6 mg/day) or 
placebo. A total of 1103 subjects were included in the analysis. 
The primary outcome measure was the change in PANSS total 
score over 6 weeks. Tolerability comparators were weight 
gain and reported AEs (adjusted for cross-program differences 
identiﬁ  ed in placebo groups). Baseline characteristics of the 
two placebo groups were similar, with the exception of a 
larger proportion of males included in the risperidone program 
and more Caucasians in the paliperidone ER program. The 
most frequently utilized schizophrenia treatment doses were 
deﬁ  ned as 4–6 mg/day of risperidone and 6–12 mg/day of 
paliperidone ER and are the most relevant for comparison. 
As such, there were 174 patients in the risperidone group and 
275 patients in the paliperidone ER dose groups. Within these 
two groups, study completion rates (65.5% for risperidone and 
67.7% for paliperidone ER) and mean PANSS changes (19.7 
for risperidone and 19.0 for paliperidone ER) were similar. 
Adverse event rates demonstrated a lower rate of akathisia, 
restlessness, anxiety, insomnia, somnolence, dizziness and 
gastrointestinal effects in the paliperidone ER group com-
pared with the risperidone group. Weight gain was slightly 
higher in the risperidone group (1.3 ± 3.7 kg) compared with 
paliperidone ER (0.7 ± 2.7 kg).
Conclusion
Paliperidone ER is indicated for the treatment of schizophrenia. 
Based on the results of the acute clinical trials, the recom-
mended starting and target dose is 6 mg once daily in the 
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Figure 6 Kaplan-Meier plot of time to recurrence – ﬁ  nal intent-to-treat analysis set (Kramer et al 2007a). Kaplan-Meier estimates for the time to recurrence of 
schizophrenia symptoms in the double-blind (ﬁ  nal analysis) group for paliperidone ER versus placebo.
Abbreviations: ER, extended release.
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morning. While higher doses may produce further beneﬁ  t, this 
strategy is mitigated by a dose-related increase in some AEs, 
such as QTc prolongation, EPS and weight gain. The recom-
mended dosing range is 3–12 mg per day. Dose adjustments of 
3 mg increments or decrements are recommended at intervals 
of not less than 5 days. For individuals with moderate-to-severe 
renal impairment (ie, creatinine clearance 10 to  50 ml/min) 
the maximum recommended dose is 3 mg per day.
Paliperidone ER (9-OH risperidone), utilizing the OROS 
delivery technology, has demonstrated efﬁ  cacy and a favorable 
tolerability proﬁ  le in the treatment of schizophrenia. This deliv-
ery system can be adapted to the speciﬁ  c properties of a drug 
to provide more stable plasma concentrations. In addition, pali-
peridone ER’s limited hepatic metabolism should lower the risks 
of related hepatic drug–drug or drug–disease pharmacokinetic 
interactions. While there are long-term data from the recurrence 
prevention study (Kramer et al 2007b), further data are needed 
to assess its potential role for long-term management (including 
a long-acting formulation) and for other disorders (eg, bipolar 
mania, schizoaffective disorder).
In the US, risperidone will be available as a generic product 
midsummer 2008. It is anticipated that the availability of this 
generic, second generation antipsychotic will impact the utili-
zation of paliperidone ER, as well as other second generation 
antipsychotics. In particular, managed care may implement 
increased restrictions on other second generation antipsychot-
ics in an attempt to increase utilization of generic risperidone. 
Unfortunately, this purely economic focus jeopardizes the 
provision of timely and appropriate clinical care to patients 
who may beneﬁ  t more from an alternate agent. Thus, with the 
pending generic formulation of risperidone, cost differences 
may impact the use of paliperidone ER. While the recently 
presented “virtual” head-to-head analysis provides some use-
ful comparison data to risperidone, adequately powered trials 
that compare paliperidone ER with other second generation 
antipsychotics (including risperidone) would be very useful 
in this context. Potential beneﬁ  ts over risperidone that may 
mitigate this issue, however, include the minimal hepatic 
metabolism in a patient population with substantial liver 
problems (eg, hepatitis C, alcohol-related) and frequent con-
current use of other hepatically metabolized psychotropic and 
non-psychotropic agents. In addition, paliperidone palmitate is 
currently in Phase III development as an aqueous, nanotechnol-
ogy-based, long-acting injectable (LAI) formulation (Rosen 
and Abribat 2005). This formulation will be different than the 
currently available risperidone LAI. The ﬁ  rst two paliperidone 
palmitate injections will be administered as a loading dose 
within 7 days of initiation. Thereafter, injections will be given 
monthly. This eliminates the need for the 3-week (or more) 
oral antipsychotic supplementation required with risperidone 
LAI. Furthermore, the ease of administration will be enhanced 
with the paliperidone LAI via utilization of pre-ﬁ  lled syringes 
that do not require refrigeration.
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